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OBJECTIVE — In type 1 diabetes, plantar fascia, a collagen-rich tissue, is susceptible to
glycation and oxidation. Paraoxonase-1 (PON1) is an HDL-bound antioxidant enzyme. PON1
polymorphisms have been associated with susceptibility to macro- and microvascular compli-
cations.Weinvestigatedtherelationshipbetweenplantarfasciathickness(PFT)andPON1gene
variants, p.Leu54Met, p.Gln192Arg, and c.-107CT, in type 1 diabetes.
RESEARCH DESIGN AND METHODS — This was a cross-sectional study of 331
adolescents with type 1 diabetes (162 male and 169 female). PFT was assessed by ultrasound,
PON1 was assessed by genotyping with PCR and restriction fragment–length polymorphism,
and serum PON1 activity was assessed by rates of hydrolysis of paraoxon and phenylacetate.
RESULTS — Median (interquartile range) age was 15.4 (13.5–17.3) years, and diabetes du-
rationwas7.6(4.9–10.6)years.Thedistributionofp.Leu54MetgenotypeswasLL135(40.8%),
ML 149 (45%), and MM 47 (14.2%). PFT was abnormal (1.7 mm) in 159 adolescents (48%).
In multivariate analysis, predictors of abnormal PFT were ML/LL versus MM p.Leu54Met poly-
morphism (odds ratio 3.84 [95% CI 1.49–9.82], P  0.005); BMI (percentile) (1.02 [1.01–
1.03], P  0.007); systolic blood pressure (percentile) (1.01 [1.00–1.02], P  0.03); and male
sex (3.29 [1.98–5.46], P  0.001).
CONCLUSIONS — Thickening of the plantar aponeurosis occurs predominantly in over-
weight and male adolescents with type 1 diabetes. The MM genotype at PON1 p.Leu54Met is
associated with a reduced risk of abnormal PFT.
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P
araoxonase-1 (PON1) is a calcium-
dependent HDL-associated enzyme
that protects LDLs from oxidation.
In type 1 diabetic patients, the serum
paraoxonase concentration is lower and
HDL is a less efﬁcient antioxidant than in
healthy individuals (1). Oxidized LDL is
implicated in the pathogenesis of athero-
sclerosis, diabetic retinopathy, and ne-
phropathy (2). Variations in lipoprotein-
related enzymes and genotypes may also
promote diabetic microvascular damage
(3).
Soft-tissue thickening is associated
with chronic hyperglycemia and is hy-
pothesizedtobeduetocollagenglycation
(4). With use of ultrasound techniques to
measure plantar aponeurosis, a collagen-
richtissue,researchersdemonstratedpre-
viously that people with diabetes have
increased plantar fascia thickness (PFT)
(5). Recently, this group reported that in-
creased PFT predicted the development
ofmicrovascularcomplicationsinadoles-
cents with type 1 diabetes and proposed
abnormal PFT as a putative marker of
soft-tissue glycation (6).
The PON gene cluster maps to chro-
mosome7q21-22andinﬂuencesgeneex-
pression and serum activity. There is an
established link between PON1 and mac-
rovascular disease (7) and emerging evi-
dence linking PON1 to microvascular
complications (8,9). In this study we in-
vestigated whether the variants c.-
107CT at the promoter region and
p.Leu54Met and p.Gln192Arg at the
coding regions of PON1 are associated
with PFT in type 1 diabetes.
RESEARCH AND METHODS—
The cohort consisted of 331 Caucasian
adolescents and young adults (162 male
and 169 female) with a median (inter-
quartile range) age of 15.4 (13.5–17.3)
years and type 1 diabetes duration of 7.6
(4.9–10.6) years, who presented for rou-
tinecomplicationsassessmentattheChil-
dren’s Hospital at Westmead (Sydney,
Australia) between 1998 and 2004. The
study was approved by the hospital’s eth-
ics committee, and written informed con-
sent was obtained.
PFT measurement
Asingleinvestigator(A.D.)measuredPFT
using ultrasound (Acuson 128 gray scale
imager; Acuson, Mountain View, CA).
For aponeurosis measurements, a linear-
array, 7-MHz high-resolution transducer
was placed longitudinally over the center
ofthearchatleast3cmfromthecalcaneal
insertion. To assess test-retest variability,
fourindividualswereassessed10timesin
the same session. The assessor was
masked to the measurements until they
were completed and stored. The intra-
class coefﬁcient was 0.89. Abnormal PFT
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the mean measurement of 57 age-
matched unrelated nondiabetic control
subjects(27male,medianage15.6years)
(5).
PON1 genotyping
DNAwasextractedfromperipheralwhite
blood cells collected in lithium-heparin
tubes using a modiﬁed salting out proto-
col. Polymorphisms were analyzed by
PCR-restriction fragment–length poly-
morphism using a slightly modiﬁed ver-
sion of the procedure described by
Humbert et al. (10). DNA (100 ng) was
denatured (94°C, 12 min) and then am-
pliﬁed for 35 cycles using PCR primers.
Each cycle consisted of denaturation
(94°C, 30 s), annealing (55°C, 30 s), and
extension (72°C, 30 s) with a ﬁnal exten-
sion of 5 min. For p.Leu54Met geno-
typing, the 171-bp PCR product was
digested (37°C, 2 h) with Hsp92II (Pro-
mega, Madison, WI), and products were
separated by PAGE (10%) and stained by
ethidium bromide. The leucine allele cor-
responded to the presence of a non-
digested fragment of 171 bp; the
methionine allele corresponded to two
digestion fragments of 127 and 44 bp.
For p.Gln192Arg genotyping, the
99-bp PCR product was digested with
DpnII, and products were separated by
PAGE (10%). The arginine allele corre-
sponded to the presence of three diges-
tion fragments (40, 31, and 28 bp); the
glutamine allele corresponded to two di-
gestion fragments of 59 and 40 bp.
For c.-107CT genotyping, the
240-bp PCR product was digested with
BsrBI, and products were separated by
PAGE (10%). The TT genotype corre-
sponded to a nondigested 240-bp frag-
ment, the CC genotype corresponded to
two digestion fragments of 212 and 28
bp,andtheCTgenotypecorrespondedto
three digestion fragments of 240, 212,
and 28 bp.
PON1 activity
In a representative subgroup of subjects
(n  144), PON1 activity of lithium-
heparinplasmawasmeasuredbytherates
of hydrolysis of paraoxon and phenylace-
tate as described previously (9).
Other variables
A1C was measured by a Bio-Rad Diamat
analyzer (nondiabetic range of 4–6%;
Bio-Rad Laboratories, Hercules, CA).
Nonfasting plasma cholesterol was mea-
sured by Cobas Mira. Systolic blood pres-
sure (SBP), diastolic blood pressure
(DBP), and BMI percentiles were deter-
mined using age- and sex-related refer-
ence standards.
Statistical analysis
Descriptive statistics are reported as
means  SD or median (interquartile
range) for skewed distributions. Groups
were compared by 
2 test for categorical
variables. Differences between indepen-
dent samples were evaluated using Stu-
dent’s t test and one-way ANOVA for
normally distributed data or the Mann-
Whitney U test for skewed data.
Multiple logistic regression was used
to evaluate the association between ab-
normal PFT and biological and genetic
variables. Explanatory variables were sex,
age, diabetes duration, A1C, BMI, SBP,
cholesterol, and PON1 genotypes (MM
vs.ML/LLforp.Leu54Met;QQvs.RQ/RR
for p.Gln192Arg, and TT vs. CT/CC for
c.-107CT). Results are expressed as
odds ratios and 95% CI. P  0.05 indi-
cated statistical signiﬁcance.
RESULTS— Clinical characteristics
are summarized in Table 1. Patients with
abnormal PFT had higher SBP and BMI
percentiles and were more likely to be
male. PON1 activity was not signiﬁcantly
different between those with or without
abnormal PFT for any substrate.
Table 2 shows genotype distributions
and allele frequencies (all mutations were
in Hardy-Weinberg equilibrium). Activi-
ties for phenylacetate and paraoxon sub-
strates were higher for patients carrying
LL alleles at PON1 p.Leu54Met versus
those with the MM genotype. Similarly,
those with CC alleles at c.-107CT had
higherenzymeactivityforbothsubstrates
versus those with the TT genotype. At
p.Gln192Arg, enzyme activity for hydro-
lysisofparaoxonwashigherinthosewith
the RR versus the QQ genotype, but phe-
nylacetate activities did not differ.
The p.Leu54Met genotype distribu-
tiondifferedbetweenthetwoPFTgroups.
The MM genotype was less frequent
among those with thickened aponeurosis
(normal PFT 20% vs. abnormal PFT 8%,

2, P  0.01). There was no difference in
frequency of p.Gln192Arg or c.-107CT
genotype distribution by PFT (Table 3).
In the multiple regression, LL/ML at
p.Leu54Met, male sex, and BMI and SBP
percentiles were associated with in-
creased PFT (Table 4). There was no in-
teraction between sex and BMI, sex and
PON1 variants, or BMI and PON1 vari-
ants. There was strong linkage disequilib-
rium between p.Leu54Met and
p.Gln192Arg and between p.Leu54Met
and c.-107CT genotypes (not shown).
Table 1—Clinical characteristics of young subjects with type 1 diabetes with and without abnormal PFT
Normal PFT Abnormal PFT Total P value
n 172 159 331
Age (years) 15.7 (13.5–17.3) 15.1 (13.5–17.3) 15.4 (13.5–17.3) 0.46
Sex (male/female) 62/110 100/59 172/159 0.001
Diabetes duration (years) 7.6 (5.0–10.3) 7.9 (4.3–11.0) 7.6 (4.9–10.6) 0.77
A1C (%) 8.6  1.3 8.5  1.1 8.6  1.3 0.69
Total cholesterol (mmol/l) 4.3 (3.9–5.0) 4.3 (3.8–4.8) 4.3 (3.8–4.9) 0.42
SBP (percentile) 54 (27–82) 71 (38–85) 59 (32–82) 0.004
DBP (percentile) 73 (48–83) 73 (48–87) 73 (48–84) 0.49
BMI (percentile) 74 (56–87) 78 (63–91) 76 (61–88) 0.02
PON1 activity*
Paraoxon (units/ml) 39.6 (28.3–79.3) 45.4 (28.1–85.4) 41.4 (28.4–79.9) 0.41
Phenylacetate (units/ml) 64.9 (44.6–81.6) 70.6 (56.7–80.4) 66.7 (52.8–80.5) 0.26
Data are means  SD or median (interquartile range). *PON1 activity was measured in 144 subjects.
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report demonstrating an association be-
tween PFT, a marker of tissue glycation
and/or oxidation, and PON1 gene poly-
morphisms in type 1 diabetes. In this
cross-sectional study, the L allele at the
p.Leu54Met gene was associated with ab-
normal PFT, or, conversely, the M allele
had a protective effect. These results sup-
port the association between PON1 gene
polymorphisms and plantar fascia
changes. Previously, our group showed
that the LL genotype was closely associ-
ated with microvascular complications
(9,11).
After a relatively short median diabe-
tesdurationof7years,approximatelyhalf
of the cohort had abnormal plantar fascia
measurements. The early appearance of
abnormal PFT, although unrelated to
A1C measured at the time of the assess-
ment, does not exclude the possibility
that early glycemic variability could leave
an imprinting in target organs, including
changes in collagen, predisposing these
organs to the future development of com-
plications. In support of this possibility,
we have recently demonstrated that PFT
predicts retinopathy, early elevation of al-
bumin excretion rate, and nerve abnor-
malities in young people with type 1
diabetes (6).
Oxidative stress and abnormalities of
lipoprotein quantity and quality are im-
plicated in the pathogenesis of microvas-
cular complications (3). We hypothesize
thatgeneticvariantsatthePON1gene,for
anantioxidantenzyme,couldalsopredis-
pose to collagen abnormalities via ad-
vanced glycation end product (AGE)
formation, which involves glycation and
oxidation. Tissue glycation and/or oxida-
tionviaintra-andextracellulargeneration
of AGEs may promote diabetes complica-
tions. The Diabetes Control and Compli-
cations Trial/Epidemiology of Diabetes
Interventions and Complications (DCCT/
EDIC) demonstrated in skin biopsies that
collagen AGEs predict microvascular dis-
ease (12). Skin collagen methionine sul-
foxide, a marker of oxidative damage
independent of glycemia, has also been
associated with type 1 diabetes complica-
tions (13).
There are divergent reports of PON1
activity and genotype and their relation-
ship to microvascular complications. Our
groupdescribedahigherallelicfrequency
of leucine 54 among type 1 diabetic sub-
jects with versus without retinopathy
(14). Similar ﬁndings were subsequently
conﬁrmed in a larger cohort of 372 type 1
Table 2—Allele frequencies and enzyme activity of PON1 genotypes for hydrolysis of paraoxon and phenylacetate as substrates
Polymorphism Genotype (n)
Frequency
(Hardy-Weinberg)
Paraoxon
(units/ml) Phenylacetate (units/ml)
n 331 144 144
p.Leu53Met LL (135) 0.40 (0.39) 77.8 (46.2–106.5) 73.4 (64.9–87.7)
ML (149) 0.45 (0.46) 39.1 (28.4–64.7) 66.2 (53.0–80.9)
MM (47) 0.14 (0.13) 21.0 (16.7–30.4) 56.0 (39.5–63.0)
P value 0.001 0.001
p.Gln191Arg RR (29) 0.09 (0.08) 99.8 (73.0–185.0) 68.2 (32.2–85.8)
RQ (127) 0.38 (0.39) 80.3 (63.4–106.1) 68.7 (54.6–80.1)
QQ (175) 0.53 (0.52) 30.5 (24.5–39.8) 66.7 (53.1–81.7)
P value 0.001 0.81
c.-107CT* CC (90) 0.27 (0.26) 61.4 (37.9–90.3) 77.4 (68.4–90.2)
CT (154) 0.49 (0.49) 40.3 (28.7–82.3) 70.3 (59.4–81.6)
TT (75) 0.24 (0.24) 34.6 (20.8–73.6) 54.0 (39.7–63.2)
P value 0.017 0.001
Data are median (interquartile range) unless otherwise indicated. *For c.-107CT, genotyping was performed in 319 individuals and PON1 activity measured in
139 subjects.
Table 3—Distribution of PON1 genotype in subjects with type 1 diabetes with and without
abnormal PFT
Normal PFT Abnormal PFT P value
p.Leu54Met
LL 66 (38) 69 (43)
ML 72 (42) 77 (49) 0.01
MM 34 (20) 13 (8)
p.Leu54Met
MM 34 (20) 13 (8)
ML/LL 138 (80) 146 (92) 0.003
p.Gln192Arg
RR 14 (8) 15 (9)
RQ 64 (37) 63 (40) 0.81
QQ 94 (55) 81 (51)
p.Gln192Arg
QQ 94 (55) 81 (51)
RQ/RR 78 (45) 78 (49) 0.58
c.-107CT
TT 41 (25) 34 (22)
CT 76 (46) 78 (51) 0.65
CC 49 (29) 41 (27)
c.-107CT
TT 41 (25) 34 (22)
CT/CC 125 (75) 119 (78) 0.69
Data are n (%).
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notype increased risk for early retinopa-
thy by almost threefold (8). The presence
of the LL genotype and two other PON1
polymorphisms was found to inﬂuence
urinary albumin excretion in 156 Cauca-
sian type 1 diabetic adolescents (9). In
contrast, others found no correlation be-
tween microvascular complications and
PON1polymorphismsinadultswithtype
1 diabetes (15). Divergent results may be
explained by differences in ethnicity, age,
sample size, smoking, diet, concomitant
medications (16), PON1 assays, and dif-
feringrelationshipsbetweenPONactivity
orgenotypeforinitiationandprogression
of complications.
Conversely, there is strong evidence
showing that “high-expressor” PON1 al-
leles inﬂuence macrovascular disease.
Homozygosity for the L allele doubled
cardiovascular disease risk after adjust-
ment for other risk factors in diabetes
(17).
If PON1 protects lipids from oxida-
tion, one might expect a higher expressor
alleleandahigherenzymaticactivitytobe
protective against oxidative stress, AGE
formation, and diabetes complications.
However, the artiﬁcial nature of the sub-
stratesinthisstudyisrecognizedandmay
not represent physiological substrates. A
recent report demonstrated that the pri-
mary activity of the paraoxonases is that
of a lactonase (18). As yet, there are no
studies relating lactonase activity to dia-
betes complications.
Although PON1 activity was mea-
sured in a subgroup of subjects, PON1
polymorphisms inﬂuenced at least one of
the two measured activities, in agreement
with published data (19). PON1 activity
was higher in the abnormal PFT group
butdidnotachievestatisticalsigniﬁcance.
There is a large interindividual variation
in PON activity that mostly depends on
functional and promoter variations at the
PON gene. Lower PON activity has been
reportedintype1diabeticsubjectsversus
control subjects regardless of differences
in PON1 phenotype (20). Hyperglycemia
may inﬂuence the in vivo concentration
andinvitroactivityofPON1.Kordonouri
et al. (11) showed that higher PON1 ac-
tivity was associated with high glucose
levelsbutnotwithA1C.Withadjustment
for blood glucose and diabetes duration,
PON1activitywashigherinsubjectswith
different stages of retinopathy versus
those without retinopathy.
Our ﬁndings suggest that high-
expressor alleles and a higher enzymatic
activity are associated with increased sus-
ceptibility to microvascular complica-
tions (8,9,11). One explanation could be
that although paraoxonase hydrolyzes
harmfullysolipidsproducedbyperoxida-
tion, it might also increase their produc-
tion from phospholipid peroxidation
products and create a more harmful li-
poprotein proﬁle. The LL genotype has
been shown to be least protective against
oxidation (21). Another possibility is that
relatively reduced enzyme activity rather
than increased absolute PON1 activity
promotes vascular complications. Some
have reported that a higher LDL choles-
terol–to-PONconcentrationratiomayin-
dicateareducedcapacityoftheenzymeto
limitLDLoxidation(22).Thelow-activity
allele at the PON1 gene has also been as-
sociated with a less harmful lipoprotein
proﬁle(23).DataontheLDLcholesterol–
to-PON concentration ratio or levels of
LDL cholesterol, triglycerides, and apoli-
poprotein B were not available for this
study.
Male sex presented a threefold in-
creasedriskforthickenedaponeurosisin-
dependent of other risk factors. The
reasons for this are unclear, but men have
a greater risk of lower limb diabetes com-
plications (24). Hormonal variation and
different recreational activities may be
contributors. Although level of physical
activity was not measured, it is unlikely
thatplantarfasciitis,acommoncondition
among athletes, is the cause of fascia
thickness. Fasciitis is associated with heel
pain, and its ultrasonographic changes
are limited to the proximal insertion of
the aponeurosis (25).
Higher BMI and SBP were associated
with abnormal PFT. Although BMI may
increase mechanical load on the plantar
aponeurosis, overweight is associated
with microvascular complications in dia-
betes, insulin resistance, hypertension,
and an atherogenic proﬁle.
In summary, this study underlines
theassociationbetweenp.Leu54Metvari-
ants and PFT, implicating PON1 in the
pathogenesis of diabetes-related collagen
changes. Although relationships between
PON1 genes and collagen abnormalities
merit further investigation, these initial
ﬁndingssupporttheconceptofPON1ge-
neticvariantsasalinkpredisposingtode-
velopment of complications in type 1
diabetes.
Acknowledgments— This study was sup-
ported by a Diabetes Australia Research Trust
New Millennium Grant.
We thank Connie Karschimkus and Chee
Lee for PON1 activity measurements.
References
1. Ferretti G, Bacchetti T, Busni D, Rabini
RA, Curatola G: Protective effect of para-
oxonase activity in high-density lipopro-
teins against erythrocyte membranes
peroxidation: a comparison between
healthy subjects and type 1 diabetic pa-
tients. J Clin Endocrinol Metab 89:2957–
2962, 2004
2. Kennedy AL, Lyons TJ: Glycation, oxida-
tion,andlipoxidationinthedevelopment
of diabetic complications. Metabolism 46:
14–21, 1997
3. JenkinsAJ,RowleyKG,LyonsTJ,BestJD,
Hill MA, Klein RL: Lipoproteins and dia-
betic microvascular complications. Curr
Pharm Des 10:3395–3418, 2004
4. JamesVJ,DelbridgeL,McLennanSV,Yue
DK: Use of X-ray diffraction in study of
human diabetic and aging collagen. Dia-
betes 40:391–394, 1991
5. Dufﬁn AC, Lam A, Kidd R, Chan AKF,
Donaghue KC: Ultrasonography of plan-
tar soft tissues thickness in young people
withdiabetes.DiabetMed19:1009–1013,
2002
6. Craig ME, Dufﬁn AC, Gallego PH, Lam A,
CusumanoJ,HingS,DonaghueK:Plantar
fascia thickness, a measure of tissue gly-
cation, predicts the development of com-
plications in adolescents with type 1
diabetes. Diabetes Care In press
7. Mackness MI, Mackness B, Durrington
PN: Paraoxonase and coronary heart dis-
ease. Atheroscler Suppl 3:49–55, 2002
8. Kao Y, Donaghue KC, Chan A, Bennetts
BH, Knight J, Silink M: Paraoxonase gene
Table 4—Factors associated with abnormal PFT in young subjects with type 1 diabetes using
multiple regression analysis
Odds ratio (95% CI) P value
p.Leu54Met (ML/LL vs. MM) 3.84 (1.49–9.82) 0.005
Sex (male) 3.29 (1.98–5.46) 0.001
BMI (percentile) 1.02 (1.01–1.03) 0.007
SBP (percentile) 1.01 (1.001–1.02) 0.03
The variables explained 19% of variation of abnormal PFT.
Plantar fascia thickness and PON1 gene
1588 DIABETES CARE, VOLUME 31, NUMBER 8, AUGUST 2008clusterisageneticmarkerforearlymicro-
vascular complications in T1DM.Diabet
Med 19:212–215, 2002
9. HoferSE,BennettsB,ChanAK,Holloway
B, Karschimkus C, Jenkins AJ, Silink M,
Donaghue KC: Association between PON
1 polymorphisms, PON activity and dia-
betes complications. J Diabetes Complica-
tions 20:322–328, 2006
10. Humbert R, Adler DA, Disteche CM, Has-
sett C, Omiecinski CJ, Furlong CE: The
molecularbasisofthehumanserumpara-
oxonase activity polymorphism. Nat
Genet 3:73–76, 1993
11. Kordonouri O, James RW, Bennetts B,
Chan A, Kao YL, Danne T, Silink M,
Donaghue K: Modulation by blood glu-
coselevelsofactivityandconcentrationof
paraoxonase in young patients with type
1 diabetes mellitus. Metabolism 50:657–
660, 2001
12. Genuth S, Sun W, Cleary P, Sell DR,
Dahms W, Malone J, Sivitz W, Monnier
VM: Glycation and carboxymethyllysine
levels in skin collagen predict the risk of
future10-yearprogressionofdiabeticret-
inopathy and nephropathy in the DCCT
and epidemiology of diabetes interven-
tions and complications participants with
type 1 diabetes. Diabetes 54:3103–3111,
2005
13. Yu Y, Thorpe SR, Jenkins AJ, Shaw JN,
Sochaski MA, McGee D, Aston CE, Or-
chard TJ, Silvers N, Peng YG, McKnight
JA, Baynes JW, Lyons TJ: Advanced gly-
cation end-products and methionine sul-
phoxide in skin collagen of patients with
T1DM. Diabetologia 49:2488–2498,
2006
14. Kao YL, Donaghue K, Chan A, Knight J,
Silink M: A variant of paraoxonase
(PON1) gene is associated with diabetic
retinopathy in IDDM. J Clin Endocrinol
Metab 83:2589–2592, 1998
15. Araki S, Makita Y, Canani L, Ng D, War-
ram JH, Krolewski AS: Polymorphisms of
human paraoxonase 1 gene (PON1) and
susceptibility to diabetic nephropathy in
type I diabetes mellitus. Diabetologia 43:
1540–1543, 2000
16. Aviram M, Rosenblat M: Paraoxonases
and cardiovascular diseases: pharmaco-
logical and nutritional inﬂuences. Curr
Opin Lipidol 16:393–399, 2005
17. Garin MC, James RW, Dussoix P, Blanche
H,PassaP,FroguelP,RuizJ:Paraoxonase
polymorphism Met-Leu54 is associated
with modiﬁed serum concentrations of
the enzyme. A possible link between the
paraoxonase gene and increased risk of
cardiovascular disease in diabetes. J Clin
Invest 99:62–66, 1997
18. Khersonsky O, Tawﬁk DS: Structure-re-
activity studies of serum paraoxonase
PON1 suggest that its native activity is
lactonase. Biochemistry 44:6371–6382,
2005
19. Brophy VH, Hastings MD, Clendenning
JB, Richter RJ, Jarvik GP, Furlong CE:
Polymorphisms in the human paraoxo-
nase (PON1) promoter. Pharmacogenetics
11:77–84, 2001
20. Abbott CA, Mackness MI, Kumar S, Boul-
ton AJ, Durrington PN: Serum paraoxo-
nase activity, concentration, and phe-
notype distribution in diabetes mellitus
and its relationship to serum lipids and
lipoproteins. Arterioscler Thromb Vasc Biol
15:1812–1818, 1995
21. Mackness MI, Durrington PN, Mackness
MI, Durrington PN: HDL, its enzymes
and its potential to inﬂuence lipid peroxi-
dation. Atherosclerosis 115:243–253,
1995
22. James RW, Leviev I, Ruiz J, Passa P,
FroguelP,GarinMC,JamesRW,LevievI,
Ruiz J, Passa P, Froguel P, Garin MC: Pro-
moter polymorphism T(107)C of the
paraoxonase PON1 gene is a risk factor
for coronary heart disease in type 2 dia-
betic patients. Diabetes 49:1390–1393,
2000
23. Hegele RA, Brunt JH, Connelly PW: A
polymorphism of the paraoxonase gene
associated with variation in plasma li-
poproteinsinageneticisolate.Arterioscler
Thromb Vasc Biol 15:89–95, 1995
24. Dufﬁn AC, Donaghue KC, Potter M,
McInnes A, Chan AK, King J, Howard NJ,
Silink M: Limited joint mobility in the
handsandfeetofadolescentswithT1DM.
Diabet Med 16:125–130, 1999
25. Wall JR, Harkness MA, Crawford A: Ul-
trasound diagnosis of plantar fasciitis.
Foot Ankle 14:465–470, 1993
Gallego and Associates
DIABETES CARE, VOLUME 31, NUMBER 8, AUGUST 2008 1589